Mobile

A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003073-18

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of the study are: •To determine how the drug [14C]-RPC1063 moves through the body and how fast it is removed from the body •To assess the amount of radioactivity found in blood, urine and faecal samples after a single dose of [14C]-RPC1063

Critère d'inclusion

  • The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for adult patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD)

Liens